---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-051565"
form_type: "8-K"
ticker: "GERN"
cik: "0000886744"
company_name: "GERON CORP"
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T01:27:58.315515+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Geron Q1 net loss $55.4M ($0.09/shr); PDUFA for imetelstat June 16, 2024

## Summary
- Q1 net loss of $55.4M ($0.09/shr) vs $38.1M ($0.07/shr) in Q1 2023; revenue $304K.
- Cash and marketable securities $465M as of March 31, 2024; $80M principal debt outstanding.
- FDA ODAC voted 12-2 in favor of imetelstat benefit/risk for lower-risk MDS; PDUFA date June 16, 2024.
- IMpactMF trial timelines extended 6 months: interim analysis now early 2026, final early 2027.
- FY2024 total operating expense guidance $270M-$280M; commercial team onboarded in April.

## SEC filing metadata
- accession: 0000950170-24-051565
- form_type: 8-K
- ticker: GERN
- cik: 0000886744
- company_name: GERON CORP
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886744/000095017024051565/0000950170-24-051565-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886744/000095017024051565/gern-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-051565
- JSON: https://secwatch.observer/filing/0000950170-24-051565.json
- Plain text: https://secwatch.observer/filing/0000950170-24-051565.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.